Two antiretrovirals with the potential for once-weekly oral dosing were unveiled at the Conference on Retroviruses and Opportunistic Infections (CROI 2024) in Denver on Monday.
The new agents have undergone phase I studies, which establish appropriate dosing and weed out drugs which have serious side effects. Before becoming available for prescription, drugs go through two further phases of testing to establish their efficacy, dosing and safety. During these stages of development many products fall by the wayside either because unexpected problems arise or the commercial priorities of the pharmaceutical company change.
It can take three to five years for new agents to complete these phases of testing, so the antiretrovirals presented this week are unlikely to change patterns of antiretroviral treatment in the near future. But they do offer a clear indication of the direction that pharmaceutical companies are heading in the antiretroviral drugs market – less frequent dosing, for both treatment and PrEP.
Read the full story at Aidsmap.
Source : Aidsmap
Related HIV and Co-Infections News
Get involved
Are you living with HIV/AIDS? Are you part of a community affected by HIV/AIDS and co-infections? Do you work or volunteer in the field? Are you motivated by our cause and interested to support our work?
Subscribe
Stay in the loop and get all the important EATG updates in your inbox with the EATG newsletter. The HIV & co-infections bulletin is your source of handpicked news from the field arriving regularly to your inbox.